Literature DB >> 10818030

The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis.

J Protheroe1, T Fahey, A A Montgomery, T J Peters.   

Abstract

OBJECTIVE: To investigate the impact of patients' preferences for the treatment of atrial fibrillation, by using individualised decision analysis combining probability and utility assessments into a decision tree.
DESIGN: Observational study based on interviews with patients.
SETTING: Eight general practices in Avon. PARTICIPANTS: 260 randomly selected patients aged 70-85 years with atrial fibrillation. MAIN OUTCOME MEASURES: Patients' treatment preferences regarding anticoagulation treatment (warfarin) after individualised decision analysis; comparison of these preferences with treatment guidelines on the basis of comorbidity and absolute risk and compared with current prescription.
RESULTS: Of 195 eligible patients, 97 participated in decision making using decision analysis. Among these 97, the decision analysis indicated that 59 (61%; 95% confidence interval 50% to 71%) would prefer anticoagulation treatment-considerably fewer than those who would be recommended treatment according to guidelines. There was marked disagreement between the decision analysis and guideline recommendations (kappa=0.25 or less). Of 38 patients whose decision analysis indicated a preference for anticoagulation, 17 (45%) were being prescribed warfarin; on the other hand, 28 (47%) of 59 patients were not being prescribed warfarin although the results of their decision analysis suggested they wanted to be.
CONCLUSIONS: In the context of shared decision making, individualised decision analysis is valuable in a sizeable proportion of elderly patients with atrial fibrillation. Taking account of patients' preferences would lead to fewer prescriptions for warfarin than under published guideline recommendations. Decision analysis as a shared decision making tool should be evaluated in a randomised controlled trial.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10818030      PMCID: PMC27382          DOI: 10.1136/bmj.320.7246.1380

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  30 in total

Review 1.  Why do patients with atrial fibrillation not receive warfarin?

Authors:  T J Bungard; W A Ghali; K K Teo; F A McAlister; R T Tsuyuki
Journal:  Arch Intern Med       Date:  2000-01-10

2.  A two-stage trial design for testing treatment, self-selection and treatment preference effects.

Authors:  G Rücker
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

3.  Risk stratification in the management of atrial fibrillation in the community.

Authors:  T Fahey; J Rimmer; P Godfrey
Journal:  Br J Gen Pract       Date:  1999-04       Impact factor: 5.386

4.  Guiding individual decisions: a randomized, controlled trial of decision analysis.

Authors:  C M Clancy; R D Cebul; S V Williams
Journal:  Am J Med       Date:  1988-02       Impact factor: 4.965

5.  The Cochrane Lecture. The best and the enemy of the good: randomised controlled trials, uncertainty, and assessing the role of patient choice in medical decision making.

Authors:  K McPherson
Journal:  J Epidemiol Community Health       Date:  1994-02       Impact factor: 3.710

Review 6.  Decision aids for patients facing health treatment or screening decisions: systematic review.

Authors:  A M O'Connor; A Rostom; V Fiset; J Tetroe; V Entwistle; H Llewellyn-Thomas; M Holmes-Rovner; M Barry; J Jones
Journal:  BMJ       Date:  1999-09-18

7.  Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation.

Authors:  R Thomson; D Parkin; M Eccles; M Sudlow; A Robinson
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

8.  The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.

Authors:  T R Lancaster; D E Singer; M A Sheehan; L B Oertel; S W Maraventano; R A Hughes; J P Kistler
Journal:  Arch Intern Med       Date:  1991-10

9.  A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage.

Authors:  J Bamford; P Sandercock; M Dennis; J Burn; C Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-01       Impact factor: 10.154

10.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.

Authors: 
Journal:  Lancet       Date:  1993-11-20       Impact factor: 79.321

View more
  71 in total

1.  Is population coronary heart disease risk screening justified? A discussion of the National Service Framework for coronary heart disease (Standard 4).

Authors:  A Rouse; P Adab
Journal:  Br J Gen Pract       Date:  2001-10       Impact factor: 5.386

2.  Quality, general practice, and the NHS plan.

Authors:  L F Smith
Journal:  Br J Gen Pract       Date:  2001-04       Impact factor: 5.386

3.  Outreach clinics in the new NHS: not yet the end of outpatients.

Authors:  S Gillam
Journal:  Br J Gen Pract       Date:  2001-04       Impact factor: 5.386

Review 4.  Understanding risk and lessons for clinical risk communication about treatment preferences.

Authors:  A Edwards; G Elwyn
Journal:  Qual Health Care       Date:  2001-09

Review 5.  How do patients' treatment preferences compare with those of clinicians?

Authors:  A A Montgomery; T Fahey
Journal:  Qual Health Care       Date:  2001-09

Review 6.  Measuring patients' preferences for treatment and perceptions of risk.

Authors:  A Bowling; S Ebrahim
Journal:  Qual Health Care       Date:  2001-09

7.  Long term anticoagulation or antiplatelet treatment. Only warfarin has been shown to reduce stroke risk in patients with atrial fibrillation.

Authors:  J G Cleland; G C Kaye
Journal:  BMJ       Date:  2001-07-28

Review 8.  Case report of paroxysmal atrial fibrillation and anticoagulation.

Authors:  Shmuel Reis; Doron Hermoni; Pnina Livingstone; Jeffrey Borkan
Journal:  BMJ       Date:  2002-11-02

9.  Re-evaluating revalidation and appraisal.

Authors:  Mike Pringle
Journal:  Br J Gen Pract       Date:  2003-06       Impact factor: 5.386

10.  Severe acute respiratory syndrome--novel virus, recurring theme.

Authors:  Anthony Harnden; Richard Mayon-White
Journal:  Br J Gen Pract       Date:  2003-06       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.